Selective peripheral tissue response to high testosterone levels in an infertile woman without virilization signs.


Journal

Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943

Informations de publication

Date de publication:
01 Apr 2024
Historique:
received: 07 10 2023
accepted: 13 03 2024
medline: 6 4 2024
pubmed: 6 4 2024
entrez: 5 4 2024
Statut: epublish

Résumé

Total testosterone, which is peripherally converted to its biologically active form dihydrotestosterone (DHT), is the first-line hormone investigation in hyperandrogenic states and infertility in premenopausal women. Polycystic ovary syndrome (PCOS), the most common cause of hyperandrogenism and infertility in young women, is often associated with mild elevations of total testosterone. Whereas very high levels of total testosterone (>2-3 SD of normal reference), are most often associated with hyperandrogenic signs, menstrual irregularity, rapid onset of virilization, and demand a prompt investigation. Herein, we report a case of a 32-year-old woman who was referred to the endocrinology outpatient clinic due to secondary amenorrhea and extremely high testosterone levels without any virilization signs. We initially suspected pitfalls in the testosterone laboratory test. Total serum testosterone decreased after a diethyl-ether extraction procedure was done prior to the immunoassay, but testosterone levels were still elevated. An ovarian steroid-cell tumor (SCT) was then revealed, which was thereby resected. Twenty-four hours post surgery, the total testosterone level returned to normal, and a month later menstruation resumed. This case emphasizes that any discrepancy between laboratory tests and the clinical scenario deserves a rigorous evaluation to minimize misinterpretation and errors in diagnosis and therapeutic approach. Additionally, we describe a possible mechanism of disease: a selective peripheral target-tissue response to high testosterone levels that did not cause virilization but did suppress ovulation and menstruation. Total testosterone is the most clinically relevant hormone in investigating hyperandrogenic states and infertility in premenopausal women. Very high total testosterone levels in women (>2-3 SD of normal reference) are most often associated with hyperandrogenic signs, menstrual irregularities, and a rapid onset of virilization. In women with very elevated testosterone levels and the absence of clinical manifestations, laboratory interference should be suspected, and diethyl ether extraction is a useful technique when other methods fail to detect it. Ovarian steroid cell tumors (SCT) encompass a rare subgroup of sex cord-stromal tumors and usually secrete androgen hormones. SCTs are clinically malignant in 25-43% of cases. A selective response of peripheral target tissues to testosterone levels, with clinical manifestations in some tissues and no expression in others, may reflect differences in the conformation of tumor-produced testosterone molecules.

Identifiants

pubmed: 38579789
doi: 10.1530/EDM-23-0117
pii: 23-0117
doi:
pii:

Types de publication

Journal Article

Langues

eng

Auteurs

Viviana Ostrovsky (V)

Kaplan Medical Center, Diabetes, Endocrinology and Metabolic Disease Institute, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Mira Ulman (M)

Endocrinology Laboratory, Kaplan Medical Center, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Rina Hemi (R)

Endocrine Laboratory, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Samuel Lurie (S)

Women's Health Center, Ramat Aviv Gimel, Clalit Health Services, Tel Aviv, Israel.

Inon Hazan (I)

Kaplan Medical Center, Gynecology Department, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Alon Ben Ari (A)

Kaplan Medical Center, Gynecology Department, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Oleg Sukmanov (O)

Kaplan Medical Center, Pathology Department, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Tal Schiller (T)

Kaplan Medical Center, Diabetes, Endocrinology and Metabolic Disease Institute, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Alena Kirzhner (A)

Kaplan Medical Center, Diabetes, Endocrinology and Metabolic Disease Institute, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Taiba Zornitzki (T)

Kaplan Medical Center, Diabetes, Endocrinology and Metabolic Disease Institute, Hebrew University of Jerusalem, Medical School, Rehovot, Israel.

Classifications MeSH